Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Current Liabilities (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Total Current Liabilities data on record, last reported at $323.6 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 74.44% year-over-year to $323.6 million; the TTM value through Dec 2025 reached $323.6 million, up 74.44%, while the annual FY2025 figure was $323.6 million, 74.44% up from the prior year.
  • Total Current Liabilities reached $323.6 million in Q4 2025 per APLS's latest filing, up from $279.5 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $323.6 million in Q4 2025 and bottomed at $83.7 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $174.6 million, with a median of $172.0 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: soared 172.09% in 2021, then decreased 25.08% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $131.8 million in 2021, then grew by 27.12% to $167.6 million in 2022, then skyrocketed by 47.72% to $247.6 million in 2023, then fell by 25.08% to $185.5 million in 2024, then soared by 74.44% to $323.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $323.6 million in Q4 2025, $279.5 million in Q3 2025, and $200.7 million in Q2 2025.